LUPKYNIS

DRUG2 trials

Sponsors

Aurinia Pharmaceuticals Inc.

Conditions

Lupus Nephritis

Phase 4

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

RecruitingNCT07611214

Aurinia Pharmaceuticals Inc.Lupus Nephritis

Start: 2026-04-22End: 2029-03-02Target: 150Updated: 2026-08-03

Unknown Phase

A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

CompletedNCT05337124

Aurinia Pharmaceuticals Inc.Lupus Nephritis

Start: 2022-04-05End: 2025-01-31Updated: 2025-06-24